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The story of the successful management of disseminated tes-
ticular cancer (TC) is well known and is listed among the American
Society of Clinical Oncology’s top ﬁve accomplishments in cancer
medicine in the last 50 years.1,2 Using the development of highly
active systemic chemotherapy as a backbone, global outcomes
achieved in experienced centers or collaborative groups are un-
paralleled. Now,many patients presenting with TC receive no therapy
beyond orchiectomy. Those who do present with or develop more
advanced disease are most often rendered disease free with in-
expensive, relatively brief treatments. More than 95% of all patients
are cured and most enjoy high-quality, long-term survivorship.
Since the early 1970s, improvements in outcomes for patients with
germ cell tumors (GCTs) have been achieved through breakthroughs
such as the discovery and application of cisplatin-based chemotherapy,
and also by less spectacular but continuous incremental innovation in
all aspects regarding the diagnosis, treatment, and follow-up of testicular
cancer. These innovations are listed in Table 1.
High-volume centers and cooperative groups have the op-
portunity to gain broad experience, develop dedicated multidis-
ciplinary teams, and build clinical registries, large datasets, and
biorepositories. This comprehensive approach facilitates research,
drives innovation, and helps engineer improved care delivery and
improved value.
Given that TC is an uncommon disease, few institutions have
substantial and sustained experience in expert management of GCTs.
As such, globally, most patients are diagnosed and treated in low-
experience environments. Such environments do not have the op-
portunity to build multidisciplinary teams or have many repetitive
opportunities to hone decision-making and learn from errors over
time. Herein, we present the evidence supporting the favorable effect
on patient care of collaboration with highly experienced teams and
groups on global outcomes in TC.
The Hypothesis: Experience Matters
We hypothesize that there is an experience/outcome effect in
the management of GCTwith institutions or collaborative groups
that treat many patients, achieving better and more consistent
results at lower cost with fewer complications. If true, this suggests
that each patient would be best served with early and continuous
input by a multidisciplinary specialized team including experi-
enced medical oncologists, urologists, oncology nursing, pathol-
ogists, and radiologists, along with the patient and local care
providers.
Evidence Supporting Experience as an Important
Component of Improved Outcomes in GCTs
That experience matters in GCTmanagement has been noted
almost since the discovery of cisplatin as a highly active agent
in management of disseminated GCT. Early analyses from the
Swedish Norwegian Testicular Cancer Project and from western
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Scotland suggested strongly that, for patients with advanced
disseminated GCT, there was a clinically signiﬁcant difference in
survival for those treated at a large single center compared with
those treated at smaller surrounding community sites.3,4 Feuer
et al5 reported ﬁndings of an early analysis of the US SEER registry
somewhat after the widespread dissemination of cisplatin. Whereas
a dramatic improvement in outcomes in this population-based
registry was seen over the ﬁrst years after the introduction of
cisplatin, results plateaued and were noticeably inferior to those
seen at a high-volume single institution. A signiﬁcant minority of
the patients treated at Memorial Sloan Kettering Cancer Center
(MSKCC) in this study received chemotherapy by the referring
community oncologist after referral to MSKCC, with a post-
chemotherapy re-evaluation at MSKCC to determine whether
surgery was necessary. It was an early example of the value of
leveraging the expertise of a specialized center.6 Other examples are
given in Appendix Table A1 (online only).
Across the world, high-volume institutions and collaborator
groups consistently outperform the International Germ Cell Con-
sensus Classiﬁcation predictive model in good, intermediate, and
poor prognosis disease. Current data suggest that care in high-
volume centers or collaborator groups exceed International Germ
Cell Consensus Classiﬁcation predictions in good-prognosis disease
by 5%, and by 10% to 15% in intermediate and poor prognosis,
respectively.6,7 In 1999, these issues were highlighted by Feuer et al.8
In addition to citing the existing evidence, the authors called for
treatment of patients with GCT by experts at high-volume centers.
These calls have been heeded variably around the world. Some
countries have taken this to the logical extension of having all
patients managed under central guidance and triage of complicated
patients to high-volume centers. Despite having to cover large and
sparsely populated geographies, the Swedish and Norwegian
Testicular Cancer Group has been able to coordinate care and
effectively disseminate the experience of high-volume centers to
achieve consistent outcomes for these populations similar to the
best single institutions in the world.9 Other national or regional
organizational efforts are described in Appendix Table A1.
Further evidence and opinions have been forthcoming re-
cently. Albers et al,10 in a randomized clinical trial, demonstrated
inferior outcomes and complications (inﬁeld relapses) when
primary retroperitoneal lymph node dissections (RPLND) were
performed at community centers. Additional examples are listed in
Appendix Table A1.
Current Status of Provider and Institutional Experience
in the United States
Recent analysis shows that 52% of all RPLND procedures were
performed by a urologist who logged one or two cases in a 6-month
period, and just three urologists performed approximately 25% of
the RPLNDs performed for TC in the United States.11 RPLND is
a procedure where the surgical quality is essential for the outcomes
in regard to complications, relapses, survival, and quality survi-
vorship. Ratios of new patients with TC to various specialists are
described in Appendix Table A1. The average number of new
patients with TC seen by a general community medical oncologist
or radiation oncologist is less than one new patient annually.
The National Cancer Database (NCDB) available from the
American College of Surgeons provides high-level registry data for
patients with cancer in the United States.12 Approximately 1,500
institutions report to the NCDB, yet fewer than 20 see more than
20 new patients with TC annually, and the median institutional
volume of patients with stage III disease per institution is two. For
TC, although detailed information is lacking, the number of pa-
tients represented in the NCDB (79,120 patients over the most
recent 10-year period) and some baseline conclusions for this
uncommon, highly curable malignancy could be drawn.13 These
include slow uptake of modern principles of management, dis-
parity gaps for racial minorities and the poor, and a robust cor-
relation with improved survival of patients with advanced stage
disease in high-volume centers.13
In a disease with such high survival rates, it is impossible to
ﬁnd level I evidence supporting improved outcomes on the basis of
institutional volume alone. However, all data and expert consensus
strongly support improved outcomes in TC being achieved at high-
volume centers and through the use of collaborator groups. In the
US data, there are limitations to the NCDB data set analyzed,
including incomplete clinical data; inability to measure reasons for
or against referral; the possibility that sicker patients, poorer
patients, and patients in extremis may not be able to be referred to
high-volume centers; and the inﬂuence of access, ﬁnancial, and
educational status. In the opposite direction, it is difﬁcult to
measure the potentially salubrious effects of direct consultation
and indirect oversight and second opinions (a long and strong
tradition in TC) with actual care being rendered at the local in-
stitution on favorable outcomes and avoidance of errors. All told,
however, and using an Occam’s razor approach, the mostly likely
explanation is the simple one—in this uncommon disease where
best outcomes require precision in management and multidisci-
plinary decision-making, experience and repetitions do matter.
The Case for Collaboration in Management of GCTs in
the United States
In GCT guideline development groups around the world,
issues of inconsistent care, overtreatment, inconsistent decision
making, and inexperienced providers are raised frequently but
often “sotto voce.” We have observed that concerns regarding
Table 1. Incremental Improvements in Care Delivery in TC and GCT
Improvement
Accurate and rapid diagnosis, pathologic characterization of risk.
Risk-adapted chemotherapy for metastatic disease on the basis of a uniform
prognostic classiﬁcation (IGCCCG).
Understanding nuances and behavior of elevated tumor markers and
equivocal imaging.
Surgical advances: management of large primary, nerve-sparing RPLND,
ERAS, management of postchemotherapy residual.
Chemotherapy: standardized delivery to achieve near 100% dose intensity,
control of nausea and vomiting, move chemotherapy delivery primarily to
outpatient setting, appropriate use of growth factors, limited use of vascular
access devices.
Recognition and management of thrombotic risk.
Less intensive imaging and follow-up for early stage and postprimary
treatment.
Clinical and biologic characterization of risk for long-term adverse effects.
Abbreviations: ERAS, enhanced recovery after surgery; GCT, germ cell tumor;
IGCCCG, International Germ Cell Cancer Consensus Group; RPLND, retroperi-
toneal lymph node dissection; TC testicular cancer.
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offending colleagues and impeding competition are often raised
as reasons against forceful declaration of the importance of in-
volving experienced teams for best multidisciplinary decision
making and management. For instance, only recently do most
guideline sets reﬂect that all retroperitoneal lymphadenectomies
should be performed in high-volume centers, and that radio-
therapy as adjuvant treatment of stage I seminoma should be
uncommon.
There are signiﬁcant barriers to physically accessing the few
high-volume centers for GCTs in the United States, even among
willing patients and referring providers. Chief among these are
the geographic distances involved with signiﬁcant risk of unre-
imbursed travel and housing expenses, and insurance-related
barriers to access to specialty centers. There are a number of
community oncologists who have received disrespect, poor service,
and poor follow-up from high-volume centers and are un-
derstandingly reluctant to facilitate referrals.
What is particularly exciting in this modern era is that we now
have the bidirectional capacity to leverage knowledge and expe-
rience over distance cheaply and comprehensively. Potential pa-
tients within large systems can be identiﬁed electronically at the
time of suspicion of the diagnosis, diagnostic workup pathways can
be inserted into electronic medical records, and pathology slides
can be digitized and distributed electronically to centers for expert
review. Sharing of images and laboratory results is routine and the
guided gathering of patient-reported inputs and outcomes is be-
coming standard. With the availability of telepresence, expertise
virtually can show up on any doorstep.
The on-demand economy is all around us where access is
more important than ownership. Some medical groups are starting
to view expertise and oversight as a commodity deliverable in real
time to the point of care.While business plans and legal issues await
resolution, the capability exists to move deep experience and expert
team-based care locally for the beneﬁt of almost all patients.
In summary, there appears to be a clear relationship between
institutional experience and better outcomes. Although this is not
a new insight, we think it is particularly important to discuss this in
the modern era and begin remediation of consequences of care in
low-experience environments. Recent data have strengthened the
vector pointing toward experience as a critical set piece in the
management of these uncommon and highly curable malignancies.
Instant transmission of images, pathology material, and laboratory
values is routine and there is increased availability of virtual
presence. We call for the following:
1. High-volume regional centers to redouble their efforts to
create effortless access to their experience by building real-
time capacity to ingest primary diagnostic and predictive
information, including patient preference for those newly
diagnosed with GCTs, as well as developing outbound capacity
to communicate recommendations and ongoing oversight
effectively to local providers and to these patients.
2. Development of community consensus on what best deﬁnes
a high-volume center and continuous monitoring of per-
formance to maintain conﬁdence in high-volume, quality
centers of excellence.
3. Community providers to join in building such capacity and
support these efforts with indirect or direct referrals of all
patients with GCT from onset to such collaborative regional
expert systems.
4. Clinical investigators to put increased emphasis on classic
clinical trials as well as investigations including biomarker-
driven decision making, novel population-based studies using
high-quality observational data, and new cancer care delivery
research to address areas such as comparative effectiveness,
care disparities, secondary use of big data, international
management of GCT, and continued study of short- and long-
term quality of life and late effects.
5. Payers, large employers, and governments to catalyze these
efforts by insuring coverage for the work and infrastructure
required to build and sustain these regional virtual centers of
excellence as well as support triage of complex patients or
those requiring high-technology approaches to high-volume
centers.
6. Patients to understand the value of collaborative care for un-
common conditions and advocate with their local provider to
participate in information sharing with organized expert teams.
We believe experience gaps can be remediated. Selective triage,
commitment to collaboration, and modern methods of in-
formation and knowledge exchange can facilitate discussion on any
case and expedite referral when needed. Expert care and excellent
outcomes can be delivered close to home in most cases. Hence, we
believe that all patients with TC, whenever possible, should be
managed through direct or indirect contact with a high-volume
referral center.
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Appendix
Table A1. Summary of Evidence Supporting Collaboration With High-Volume Centers in Testicular Cancer
Type of Evidence Study Group and/or Location Primary Finding Conclusion
Improved survival in high-volume centers
Aass et al3 Sweden, Norway Better outcomes at large centers v small
centers.
Treatment in high-volume center improves
outcome.
Harding et al4 Scotland Lower outcomes in community setting,
centralization of care improves
outcome.
Treatment in high-volume center improves
outcome.
Feuer, et al5 MSKCC Better outcomes at MSKCC v SEER. Treatment in high-volume center improves
outcome.
Collette et al6 EORTC Decreased survival for patients treated at
centers with fewer than ﬁve patients in
the trial.
Treatment in high-volume center improves
outcome.
Outperformance of IGCCC at high-volume
centers
Necchi et al7 Italy and Indiana Improvement of 10% to 18% in
intermediate- and poor-risk disease in
high-volume centers.
High-volume centers outperform IGCCCG
results.
Countries adopting regionalized or
centralized management
Cohn-Cedermark et al9 SWENOTECA One-time BEP treatment is associated
with low relapse rate in high-risk, clinical
stage I nonseminoma. Surveillance is an
appropriate option for clinical stage I
testis cancer.
Excellent outcomes for all management
options in a centralized/regionalized care-
delivery system.
Kollmannsberger (Kollmannsberger C,
et al: J Clin Oncol 33:51-7, 2015)
SWENOTECA and Canada Disease-speciﬁc mortality with active
surveillance is low.
Active surveillance is safe in experienced
centers.
Daugaard (Daugaard G, et al: J Clin
Oncol 32:3817-23, 2014)
Denmark Disease-speciﬁc mortality with active
surveillance is low.
Active surveillance is safe in experienced
centers.
Cummins (Cummins S, et al: Eur Urol
57:673-8, 2010)
Royal Marsden Hospital Disease-speciﬁc mortality with active
surveillance is low.
Active surveillance is safe in experienced
centers.
Wells (Wells H, et al: BJU Int
119: 91–99, 2017)
England Low morbidity and mortality rates in high-
volume centers.
Consistent delivery of RPLND in high-
volume centers is associated with
excellent surgical outcomes.
Zengerling (Zengerling F, et al: Oncol
Rep 31:2477-81, 2014)
Germany 40% difference in treatment
recommendation between peripheral
care center and expert
recommendation.
Communication about and review of cases
with an expert center improves outcome.
Albers et al10 Germany RPLND in community centers is
associated with increased inﬁeld
recurrence rate and morbidity.
RPLNDs should be performed in expert
centers.
Wymers (Wymers KH, et al: J Urol.
197:684-689, 2017)
United States 30% of reviewed patients had
nonguideline-conforming–ﬁrst-line
therapy.
Nonguideline-directed care is associated
with higher relapse rate and, most likely,
higher morbidity and impaired cure rates.
Thibault (Thibault C, et al: Eur J Cancer
50:1284-90, 2014)
France 50%of referred patients had nonguideline-
conforming–ﬁrst-line therapy.
Centralization of testis cancer care
recommended.
Number of US specialists/total number
of new cases
Flum et al11 Urologists Median number of logged RPLNDs is one;
23% of all RPLNDs done by three
surgeons.
Regionalization of surgical care
recommended.
Thompson (Thompson RH, et al: Cancer
116:5243-50, 2010)
Urologists Median number of removed lymph nodes
was 38.
Higher lymph node count improves accuracy
of the procedure.
High-volume surgeons remove more lymph
nodes.
Thompson (Thompson RH, et al:
Urology 77:368-72, 2011)
Urologists Total node count associated with ﬁnding
positive nodes.
High lymph node counts in experienced
center.
(continued on following page)
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Table A1. Summary of Evidence Supporting Collaboration With High-Volume Centers in Testicular Cancer (continued)
Type of Evidence Study Group and/or Location Primary Finding Conclusion
Segelov (Segelov E, et al: Br J Urol
71:736-8, 1993)
Pathologists 32% differing ﬁndings between outside
and expert center.
Pathology review led to change in treatment
and prognosis in 11% of cases.
Berney (Berney DM, et al:
Histopathology 67:313-24, 2015)
Pathologists Signiﬁcant areas of disagreement included
staging and reporting of histologic types.
Pathology review may have impact on
treatment.
Real-world observational data: NCDB
Jeldres et al13 US NCDB 93% of pts with stage III disease are seen
in institutions with # 20 pts per year.
Improved outcomes in high-volume centers.
DeRouen (DeRouenMC, et al: J Adolesc
Young Adult Oncol 5:31-40, 2016)
California cancer registry Hispanic and black adolescents had worse
outcome.
Race and socioeconomic status affect
survival.
Low socioeconomic status is associated
with worse outcome.
Kamel (Kamel MH, et al: Urology
87:140-5, 2016)
SEER 2.64% of uninsured v 1.36% of insured
patients died of testicular cancer (P 5
.025) and 16.73% of uninsured v
10.52% of insured hadM1 at diagnosis.
Uninsured patients with testicular cancer
present with more advanced cancer
stages and have higher mortality rates
than insured patients.
Nichols (Nichols CR, et al: J Clin Oncol
32, 2014 [suppl 4; abstr 391])
NCDB Hispanic and black patients are diagnosed
with higher-stage disease and have
higher risk of death.
Race and socioeconomic status affect
survival.
Abbreviations: BEP, bleomycin, etoposide, cisplatin; EORTC, European Organization for Research and Treatment of Cancer; IGCCCG, International Germ Cell Cancer
Collaborative Group; MSKCC, Memorial Sloan Kettering Cancer Center; NCDB, National Cancer Database; RPLND, retroperitoneal lymph node dissection;
SWENOTECA, Swedish and Norwegian Testicular Cancer Group.
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